Ottawa Allergy Research Corporation

Ottawa, Ontario K1Y 4G2

1 studies enrolling now · 15 studies all time

What they study most

Allergy, Angioedema, Atopic Dermatitis, Bilateral Nasal Polyposis, Chronic Spontaneous Urticaria, Food Allergy, Hereditary Angioedema, Hereditary Angioedema (HAE), Ig-E Mediated Food Allergy, Moderate to Severe Asthma, Peanut Allergy

Studies at this site

• Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy — Recruiting now
• HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE) — Running, not enrolling
• Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma — Running, not enrolling
• Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy — Completed
• A Study of Navenibart (STAR-0215) in Participants With Hereditary Angioedema — Completed
• A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) — Running, not enrolling
• A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema — Running, not enrolling
• Efficacy and Safety of Viaskin Milk in Children With IgE-Mediated Cow's Milk Allergy — Completed
• A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor — Completed
• A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) — Completed
• Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic Dermatitis — Completed
• Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema — Completed
• Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE — Completed
• Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety — Completed